BONE MARROW ORGANOIDS

Partnership and/or Licensing Opportunities

Organoids are gaining popularity and have shown increased applications, especially in the early drug discovery and other research and development fields.

EFS research team in Toulouse has developed a unique bone marrow *ex vivo* model that incorporates all cellular and non-hematopoietic micro-environmental parameters

INVENTION

This invention comprises an innovative procedure and a culture medium to generate *in vitro* human bone marrow obtained from primary mesenchymal stromal cells without the use of a cell line. The bone marrow obtained *in vitro* reproduces physiological haematopoietic niche composed of a medullary adipose tissue, an osteoblastic compartment and a vascular network, able to support haematopoiesis.

This invention enables to cultivate bone marrow in 2D or 3D conditions either with a biomaterial or with an organoid-based strategy.

KEYWORDS

Organoids, 2D or 3D cultures, bone marrow, mesenchymal stromal cells, scaffold, alternatives to animal testing, drug discovery, haematopoiesis

DESCRIPTION

Inventors confirmed by RT-PCR and fluorescence microscopy techniques the expression of osteoblastic, adipocyte and vascular lineage after a single step differentiation in 2D or 3D cell culture which demonstrates the *in vitro* reproducibility of physiological bone marrow. Furthermore, this procedure is flexible and can be adapted to different experimental conditions (monolayer, organoids, and scaffolding).

APPLICATIONS

- Preclinical testing system for molecules
- Drug screening

ADVANTAGES

- Cost effective cell culture
- Model derived from primary mesenchymal stromal cells
- Simple, fast procedure without genetic modification
- Allows to screen drugs and molecules for potential effect on the bone marrow

CONTACTS

ÉTABLISSEMENT FRANCAIS DU SANG

Du donneur aux patients

> Principal Investigators:

Nicolas ESPAGNOLLE & Mélanie GADELORGE

Donnons au sang

le pouvoir de soigner

Toulouse (France)



https://restore-lab.fr/

Technology Transfer Office

<u>Efs-</u> <u>DirectionInnovations</u> <u>@efs.sante.fr</u>

https://www.efs.sante.fr/

INTELLECTUAL PROPERTY

Patent: PCT/2022/057229